NIH Stroke Scale certification, American Heart Association, 2020

CITI course biosafety certification, CITI Collaborative Institutional Training Initiative, 2019

Modified Rankin scale certification, American Heart Association, 2019

Board-certified in neurology, American Board of Psychiatry and Neurology, 2002 (recertified 2013)

Dr. Raymond Weichwein's research interests include telehealth; primary and secondary stroke prevention; acute stroke management, particularly acute ischemic stroke treatment and hospital care; transient ischemic attack (TIA) evaluation and management; stroke recovery; and other areas of stroke care.

In telehealth, his work focuses on the optimal use of virtual telehealth across the continuum of stroke care - acute stroke care (to include prehospital/EMS care), inpatient care, outpatient care and stroke rehabilitation.

In the area of primary and secondary stroke prevention, Dr. Reichwein is conducting an ongoing primary care provider (PCP)-focused project, first identifying high-risk patients (based on documented risk factors and CHADS-VASC score) in advance of an upcoming patient visit to the PCP, then formulating a one-year plan to address these risk factors and provide optimal TIA/stroke education (develop a population-based health care network model).

In acute stroke management, particularly acute ischemic stroke treatment and hospital care, Dr. Reichwein has interest in optimizing stroke systems of care/networks, starting with pre-hospital EMS evaluation, then emergency department evaluation, intravenous thrombolytic therapy (tPA and tenecteplase), endovascular thrombectomy, critical care/hospitalization stroke management and post-discharge follow-up care. Dr. Reichwein is also interested in the use of advanced diagnostic testing, specifically CT (brain) perfusion and multiple-phase CT angiography, to optimally select patients for acute ischemic stroke treatments, and in optimal treatment of post-stroke cerebral edema.

In the area of transient ischemic attack (TIA) evaluation and management, Dr. Reichwein has an interest in urgent clinical evaluation, diagnostic testing and treatment interventions for suspected TIA patients.

Regarding stroke recovery, Dr. Reichwein is the principal investigator in the MASTERS-2 research trial evaluating intravenous stem cell therapy vs. placebo within 18 to 36 hours of acute ischemic stroke symptom onset. He also is beginning an investigator-initiated project on optimal medication management (dopaminergic vs. SSRI vs. other stimulant treatment) for post-stroke depression and fatigue. Dr. Reichwein also has interest in neuro-modulation, to include transcranial magnetic stimulation treatment, to optimize stroke recovery.

Finally, Dr. Reichwin is the principal investigator in the NIH-sponsored Sleep Smart research trial via StrokeNet, aimed at identifying significant obstructive sleep apnea within 14 days of TIA or stroke, then pursuing acute sleep apnea treatment with CPAP therapy (vs. no treatment) to determine if this leads to decreased subsequent recurrent TIA/stroke/vascular events and/or improves subsequent clinical outcome in stroke patients.

Dr. Raymond Reichwein has clinical interests in telehealth; primary and secondary stroke prevention; acute stroke management, particularly acute ischemic stroke treatment and hospital care; transient ischemic attack (TIA) evaluation and management; stroke recovery; and other areas of stroke care.

In telehealth, Dr. Reichwein's practice focuses on the optimal use of virtual telehealth across the continuum of stroke care - acute stroke care (to include prehospital/EMS care), inpatient care, outpatient care and stroke rehabilitation.

In the area of primary and secondary stroke prevention, Dr. Reichwein focuses on multiple common risk factors and optimal medication, plus behavioral/dietary management.

Regarding his interest in optimal atrial fibrillation identification and optimal future stroke prevention, Dr. Reichwein has interest in silent significant microvascular cerebrovascular disease and pursuit of optimal secondary stroke prevention measures. In this area, he seeks to develop a population-based health care/network stroke prevention model.

In the area of acute stroke management, particularly acute ischemic stroke treatment and hospital care, Dr. Reichwein is interested in optimizing stroke systems of care/networks, starting with pre-hospital EMS evaluation, then emergency department evaluation, intravenous thrombolytic therapies (tPA and tenecteplase), endovascular thrombectomy, critical care/hospitalization stroke management and post-discharge follow-up care. He also uses advanced diagnostic testing, specifically CT (brain) perfusion and multiple-phase CT angiography, to optimally select patients for acute ischemic stroke treatments. He is interested in the optimal treatment of post-stroke cerebral edema.

Regarding transient ischemic attack (TIA) evaluation and management, Dr. Reichwein is interested in urgent clinical evaluation, diagnostic testing and treatment interventions for suspected TIA patients.

In the area of stroke recovery, he has interest in stem cell therapy (various routes) for post-stroke recovery. He also has interest in optimal medication management (dopaminergic vs. SSRI vs. other stimulant treatment) for post-stroke depression and fatigue, and is pursuing neuro-modulation, to include transcranial magnetic stimulation treatment.

Finally, Dr. Reichwein has clinical interest in early identification of significant obstructive sleep apnea and subsequent optimal treatment to prevent recurrent ischemic events/stroke as well as decrease progression of microvascular cerebrovascular disease.